While this study does not elucidate whether IL-18 or IL-1β induced production by anti-PD-L1 would be beneficial or detrimental for cancer treatment, it pinpoints an important discrepancy between anti-PD-1 and anti-PD-L1 mAbs. This evidence concerns the gene IL18 and cancer.